


Launch of Mass Spectrometry Facility in NUI Galway



National University of Ireland, Galway
Ollscoil na hÉireann, Gaillimh



Date and Location

Thursday 29th January, 2009
Aula Maxima in the Main Quadrangle Building NUI Galway

Agenda

- | | |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09:30 - 10:00 | Registration - Tea/ Coffee |
| 10:00 - 10:15 | Welcome
<i>Speakers: Terry Smith, VP Research NUIG and Padraig McDonnell, Director Agilent Technologies Ireland</i> |
| 10:15 - 11:00 | Advanced Technologies for Analytical Measurement of biological systems
<i>Speaker: Gus Salem, LC-MS Vice-President and General Manager, Agilent Technologies</i> |
| 11:00 - 11:45 | New Quantitative Proteomics Approaches
<i>Speaker: Dr Bruno Domon; ETH Zurich,</i> |
| 11:45 - 12:30 | Recent Developments in LCMS Solutions in Agilent Technologies
<i>Speaker: John Lee, Mass Spectrometry Specialist, Agilent Technologies</i> |
| 12:30 - 13:15 | Lunch |
| 13:15 - 14:00 | Using Mass Spectrometry to Probe Endocannabinoid Signalling: a Pharmacologist's Perspective
<i>Speaker: Prof David Kendall; University of Nottingham</i> |
| 14:00 - 14:45 | Mass Spectrometric Strategies for Glycomics and Glycoproteomics.
<i>Speaker: Stuart Haslam , Imperial College London</i> |
| 14:45 - 15:30 | Facility Tour and closing remarks |
| 19.00 | Dinner for Speakers and Organisers |

Registration Details

To register for please visit: www.agilent.com/chem/NUIG



Keynote Speaker

Dr Stuart M. Haslam | Division of Molecular Biosciences, Faculty of Natural Sciences, Imperial College London

Dr Haslam's research is focused on the application of high sensitivity mass spectrometry to the determination of the structure of glycoconjugates from diverse biological origins. After obtaining his PhD from the University of Leeds, his postdoctoral research at Imperial College London on nematode parasite glycosylation laid the foundations of high sensitivity mass spectrometric analysis of complex mixtures of oligosaccharides which are now widely exploited in glycomic analysis. In recognition of this work he was awarded a Young Scientist Award by the organizing and program committees of the XIVth International Symposium on Glycoconjugates, Zurich, Switzerland. His more recent research has encompassed the structural analysis of glycoconjugates from diverse biological origins ranging from bacteria to humans. He was appointed to a lectureship in 2002 at Imperial College London and the same year he was appointed Director of the Analytical Glycotechnology Core facility associated with the NIH-funded Consortium for Functional Glycomics. The Analytical Glycotechnology Core is involved in glycomic profiling of mouse and human tissues and performing carbohydrate structure analysis on carbohydrate binding protein ligands and specific mouse and human cell lines. He is also a member of the Steering Committee of the EuroCarbDB consortium aiming to develop and distribute web-based carbohydrate data bases and he leads the Imperial College component which is responsible for mass spectrometry activities. He has also obtained Wellcome Trust funding as PI to investigate the glycan receptor of the H5N1 influenza virus.

Dr Bruno Domon | Group Leader, Institute for Molecular Systems Biology, ETH Zurich.

Bruno Domon is an expert in biological mass spectrometry and proteomics. He is currently Head of the mass spectrometry laboratory and biomarker program at the Institute for Molecular Systems Biology (Head Ruedi Aebersold) at ETH Zurich. His main focus is the development of novel mass spectrometric based proteomics methodologies, and its application to biomarker discovery and evaluation, and to proteomics in general. As Director at Celera Genomics in Rockville MD, USA (2001-2004) he led the proteomics program on drug target discovery in oncology, which resulted in the identification of cell surface proteins for therapeutic development and diagnostics. Prior to that (1998-2001), he was associated director heading of the mass spectrometry facility at Biogen in Cambridge MA, USA. From 1988 to 1994 he has occupied different functions at Ciba-Geigy (now Novartis) in Basel, Switzerland, including manager of the mass spectrometry facility. Bruno Domon studied chemistry at the University of Neuchatel, where he obtained a chemical engineering degree in 1980. He then graduated from the University of Lausanne, where he received his Ph.D. in 1984 (Isolation and structural elucidation of natural products). He then started his mass spectrometry career as post-doctoral fellow at Ciba-Geigy in Basel (1985-86) and at the department of Chemistry of the Massachusetts Institute of Technology (MIT, 1986-87). He was appointed as Professor at the Université des Sciences et Technologies de Lille in France (1994 – 1998), invited Professor at the Université Catholique de Louvain, Belgium (1996), and Visiting Scientist at Boston University School of Medicine (1998). He is author or co-author of over 50 publications published in peer-reviewed journals and inventor of several patents or patent applications.

Professor David A. Kendall | Professor of Cellular Pharmacology, School of Biomedical Sciences, University of Nottingham

Prof. Kendall's major aim has been to increase understanding of the mechanisms of action of drugs and hormones acting via receptors (mainly G protein-coupled receptors) in the brain and cardiovascular system in health and disease. By extending his PhD work in Houston, his team was able to show that sex steroid hormones were essential for the full expression of antidepressant drug activity. This study was the precursor of a number of projects demonstrating the interdependency of steroid hormones and monoamine receptors in the mode of action of psychoactive drugs. While he was in Leicester, his group was the first to develop a facile assay for the investigation of receptor-mediated phosphoinositide hydrolysis in the brain making possible an extensive series of studies investigating Gi/o protein-mediated receptor signalling, including some of the very few using human brain tissue. Over the past few years they have established a research team in Nottingham interested in the endogenous cannabinoid signalling system. Their aim is to pursue translational studies ranging from in vitro signalling to whole animal and eventually human clinical approaches. They have made important contributions to the understanding of the role of cannabinoids in pain, panic, reward and in the control of the vasculature. They are now extending these studies to investigate the roles of the endocannabinoid system in animal models of psychiatric and neurological conditions and have recently submitted a report on changes in peripheral endocannabinoids in patients with multiple sclerosis.

Gustavo Salem | Vice-President, General Manager, LC/MS Life Sciences Solutions Unit, LSCA Agilent Technologies

Gustavo "Gus" Salem brings over 20 years of life science sales, marketing, and business management experience to his new role as Vice-President and General Manager, LC/MS at Agilent Technologies. In this role, he has responsibility for the business P&L, product development, and marketing strategy for Agilent's mass spectrometry products. Gustavo joins Agilent from Assay Designs, Inc., where he served as President and CEO. Assay Designs is a venture-backed life science company with a focus on the development of immunoassays and antibodies for drug discovery research. Prior to Assay Designs, he served as Division Manager of the Protein Separations Division at Bio-Rad Laboratories, where he managed the P&L and was responsible for the chromatography and electrophoresis product lines, as well as the company's Expression Proteomics program. He has also held sales and marketing management positions at Applied Biosystems, PerSeptive Biosystems, Verax Corporation and Beckman Instruments. He holds a Masters degree in psychobiology from UC Irvine and a B.A. from UC Berkeley.

